Hemogenyx Pharmaceuticals Plc (LON:HEMO – Get Free Report) dropped 0.9% during trading on Monday. The company traded as low as GBX 540 and last traded at GBX 565. 1,286 shares were traded during mid-day trading, a decline of 94% from the average daily volume of 23,341 shares. The stock had previously closed at GBX 570.
Hemogenyx Pharmaceuticals Stock Down 0.9%
The company’s 50 day moving average price is GBX 581.62 and its two-hundred day moving average price is GBX 753.42. The company has a quick ratio of 6.72, a current ratio of 4.04 and a debt-to-equity ratio of 42.86. The stock has a market cap of £38.97 million, a P/E ratio of -4.32 and a beta of 1.49.
Hemogenyx Pharmaceuticals (LON:HEMO – Get Free Report) last released its quarterly earnings data on Monday, September 28th. The company reported GBX (101.70) earnings per share for the quarter.
About Hemogenyx Pharmaceuticals
Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.
Recommended Stories
- Five stocks we like better than Hemogenyx Pharmaceuticals
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Hemogenyx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemogenyx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
